Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IFX-1 in severe COVID-19 pneumonia
NL-OMON55215Phase 3Active, not recruiting
- Sponsor
- InflaRx
- Start
- Mar 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing SOC + IFX-1 with SOC + placebo (2 arms). Primary endpoint: 28-day all-cause mortality. Started Mar 2020; status: active, not recruiting.
02
Drugs
vilobelimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON55215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55215.